Results 21 to 30 of about 96,485 (242)

The Levels of Wnt5a and Its Receptors Frizzled5 and Frizzled2 as Immunohistochemical Biomarkers of Severity of Psoriasis

Clinical, Cosmetic and Investigational Dermatology, 2021
Xiaoying Ning, Dingwei Zhang, Yuan Wang, Jia Huo, Ying Huang, Ying Guo, Zhengxiao Li, Yanfei Zhang Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xian, Shaanxi Province, People’s Republic of ChinaCorrespondence ...
Ning X, Zhang D, Wang Y, Huo J, Huang Y, Guo Y, Li Z, Zhang Y   +7 more
doaj  

Response to Biologics During the First Six Months of Therapy in Biologic-naïve Patients with Psoriasis Predicts Risk of Disease Flares: A Danish Nationwide Study

Acta Dermato-Venereologica, 2021
Early response to treatment with biologics might be important for the stability of psoriasis and long-term outcome. The aim of this study was therefore to assess whether risk of flares and drug survival are associated with disease activity in the first 6
Nikolai Loft, Alexander Egeberg, Mads Kirchheiner Rasmussen, Lars Erik Bryld, Christoffer V. Nissen, Tomas Norman Dam, Kawa Khaled Ajgeiy, Lars Iversen, Lone Skov   +8 more
doaj   +1 more source

Plasma total antioxidant capacity and peroxidation biomarkers in psoriasis [PDF]

, 2016
Systemic biomarkers of oxidative stress can be relevant for assessment of psoriasis severity, for prediction of the outcome of therapy and of the development of comorbidities.
Cavaliere, Arturo, Palmery, Maura, Peluso, Ilaria   +2 more
core   +2 more sources

An approach to graph-based analysis of textual documents [PDF]

, 2013
In this paper a new graph-based model is proposed for the representation of textual documents. Graph-structures are obtained from textual documents by making use of the well-known Part-Of-Speech (POS) tagging technique.
Bronselaer, Antoon, Pasi, Gabriella
core   +2 more sources

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Life, 2022
Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical ...
Ricardo Ruiz-Villaverde, Lourdes Rodriguez-Fernandez-Freire, Amalia Pérez-Gil, Pilar Font-Ugalde, Manuel Galán-Gutiérrez   +4 more
doaj   +1 more source

Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review

Psoriasis: Targets and Therapy, 2022
Chanel Claudine de Ruiter, Thomas Rustemeyer Dermato-Allergology and Occupational Dermatology, Amsterdam UMC, Amsterdam, the NetherlandsCorrespondence: Thomas Rustemeyer, Dermato-Allergology and Occupational Dermatology, Amsterdam UMC, Amsterdam, the ...
de Ruiter CC, Rustemeyer T
doaj  

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study

Acta Dermato-Venereologica, 2021
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to
Antonio Costanzo, Filomena Russo, Marco Galluzzo, Luca Stingeni, Roberta Scuderi, Leonardo Zichichi, Manuela Papini, Luisa Di Costanzo, Andrea Conti, Martina Burlando, Andrea Chiricozzi, Francesca Maria Gaiani, Cristina Mugheddu, Maria Letizia Musumeci, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Marina Venturini, Gianluca Pagnanelli, Paolo Amerio, Concetta Potenza, Ketty Peris, Franca Cantoresi, Sara Trevisini, Francesco Loconsole, Annamaria Offidani, Santo Raffaele Mercuri, Viviana Lora, Francesca Prignano, Marta Bartezaghi, Giovanni Oliva, Elisabetta Aloisi, Roberto Orsenigo   +32 more
doaj   +1 more source

Monitoring the Sky with the Prototype All-Sky Imager on the LWA1

, 2015
We present a description of the Prototype All-Sky Imager (PASI), a backend correlator and imager of the first station of the Long Wavelength Array (LWA1).
Clarke, T. E., Dowell, J., Dubois, A., Dubois, D., Hartman, J. M., Henning, P. A., Lazio, J., Michalak, S., Obenberger, K. S., Schinzel, F. K., Taylor, G. B.   +10 more
core   +1 more source

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) [PDF]

, 2018
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Andersson, Mats, Blanco, Ricardo, Dokoupilova, Eva, FUTURE 3 study group, Kajekar, Radhika, McInnes, Iain B, Mease, Philip J, Mpofu, Shephard, Nash, Peter, Pricop, Luminita, Rahman, Proton, Ritchlin, Christopher T   +11 more
core   +1 more source

Evaluation of Psoriasis Area and Severity Index as a Proxy for Bio­markers of Systemic Disease under Treatment with Tumour Necrosis Factor-alpha and Interleukin 12/23 Antagonists in Patients with Psoriasis: A Retrospective Cohort Study of 186 Treatment Cycles

Acta Dermato-Venereologica, 2021
The efficacy of psoriasis treatments is usually evaluated using the Psoriasis Area and Severity Index (PASI). However, there is a lack of systematic statistical assessments of PASI as a proxy for systemic disease in individual patients.
Jochen H.O. Hoffmann, Christian Knoop, Knut Schäkel, Alexander H. Enk, Eva N. Hadaschik   +4 more
doaj   +1 more source